Literature DB >> 16710108

Myocardial perfusion imaging in the elderly: a review.

Olivier De Winter1, Nico Van de Veire, Filip Gemmel, Ingeborg Goethals, Johan De Sutter.   

Abstract

Coronary artery disease is a major cause of morbidity and mortality in the elderly population. As a result of ageing of the population and better medical, interventional and surgical treatment of patients with coronary artery disease, more and more elderly patients are referred to the cardiology department for diagnostic work-up. Stress testing, in combination with myocardial perfusion imaging, is routinely used in elderly patients, a population in which the diagnosis of significant coronary artery disease is often challenging because of atypical symptomatology. Since the introduction of technetium-99m ligands for myocardial perfusion imaging, it is possible to perform electrocardiogram-gated perfusion imaging. This not only improves the specificity of the test for coronary artery disease detection, but also enables the simultaneous assessment of left ventricular functional parameters. This article briefly overviews the possible stress modalities, diagnostic accuracy and prognostic value of myocardial perfusion imaging in elderly patients.

Entities:  

Mesh:

Year:  2006        PMID: 16710108     DOI: 10.1097/00006231-200606000-00009

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  2 in total

Review 1.  Nuclear stress testing in elderly patients: a review of its use in the assessment of cardiac risk, particularly in patients undergoing preoperative risk assessment.

Authors:  Amgad N Makaryus; Joseph A Diamond
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.